Can cyclobenzaprine (Flexeril) be used in patients with chronic kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cyclobenzaprine (Flexeril) Can Be Used in CKD Patients, But With Important Cautions

Cyclobenzaprine can be given to patients with chronic kidney disease, as it does not require renal dose adjustment and is primarily metabolized hepatically. However, the FDA drug label does not provide specific guidance for CKD patients, and caution is warranted due to its anticholinergic effects and potential for drug interactions 1.

Key Considerations for CKD Patients

No Renal Dose Adjustment Required

  • Cyclobenzaprine is predominantly metabolized in the liver, not renally excreted
  • The FDA label contains no specific contraindications or dose adjustments for renal impairment 1
  • This distinguishes it from many other medications that require careful dosing in CKD 2, 3

Important Safety Precautions

Anticholinergic Effects: Use with caution in CKD patients who may have:

  • Urinary retention (common in CKD patients)
  • Volume status issues
  • Concurrent use of other anticholinergic medications 1

Drug Interactions: Monitor carefully for:

  • Serotonin syndrome when combined with SSRIs, SNRIs, or other serotonergic agents (common in CKD patients with depression) 1
  • Enhanced CNS depression with other sedatives
  • Tricyclic antidepressant-like cardiovascular effects (arrhythmias, tachycardia) 1

Practical Management Approach

Before prescribing:

  • Review all current medications for potential interactions, especially serotonergic agents
  • Assess for urinary retention, glaucoma, or cardiac conduction abnormalities
  • Consider that CKD patients often take multiple medications, increasing interaction risk 2, 3

During treatment:

  • Start with standard dosing (no adjustment needed for CKD)
  • Monitor for anticholinergic side effects (confusion, urinary retention, constipation)
  • Watch for excessive sedation or CNS effects
  • Hold on day of surgery if procedures are planned 4

Avoid in specific situations:

  • Elderly patients (not recommended due to increased plasma levels and half-life) 1
  • Hepatic impairment of any severity (contraindicated) 1
  • Concurrent MAO inhibitor use (absolute contraindication) 1

Common Pitfalls to Avoid

  1. Don't assume all muscle relaxants are safe in CKD - while cyclobenzaprine doesn't require dose adjustment, other agents like carisoprodol or metaxalone may have different considerations 4

  2. Don't overlook polypharmacy risks - CKD patients typically take multiple medications; cyclobenzaprine's anticholinergic and serotonergic properties increase interaction potential 2, 3

  3. Don't confuse with hepatic impairment - while safe in CKD, cyclobenzaprine is not recommended in any degree of hepatic impairment due to doubled plasma levels 1

  4. Don't forget to taper if discontinuing after prolonged use - withdrawal symptoms (malaise, nausea, headache) can occur, though they are not life-threatening 4

References

3
Research

Medication considerations for patients with chronic kidney disease who are not yet on dialysis.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association, 2011

Related Questions

In a patient with an estimated glomerular filtration rate of 46.6 mL/min/1.73 m² (stage 3 chronic kidney disease) who is taking lisinopril 20 mg daily, furosemide 20 mg daily, metoprolol extended‑release 12.5 mg daily, and hydralazine 25 mg twice daily, how should these medications be managed or adjusted?
In a patient with stage 3 chronic kidney disease (eGFR ≈ 56 mL/min) and hypertension who is taking hydrochlorothiazide (HCTZ) only three times per week, is this intermittent dosing appropriate and what management should be recommended?
How should I manage a non‑pregnant adult with proteinuric chronic kidney disease and hypertension, including medication selection (ACE inhibitor or ARB, SGLT2 inhibitor, possible GLP‑1 agonist), lifestyle modifications, and follow‑up monitoring?
What is the optimal management for uncontrolled severe hypertension in a 73‑year‑old woman with stage 3‑4 chronic kidney disease (severely reduced eGFR) who is already on irbesartan 150 mg daily, amlodipine 10 mg daily, carvedilol 12.5 mg twice daily, and has bradycardia?
What is the appropriate antihypertensive management for a 56-year-old male with uncontrolled hypertension (158/79 mm Hg), asymptomatic, currently on amlodipine 10 mg daily, chronic kidney disease with eGFR 13 mL/min/1.73 m², and diabetes with hemoglobin A1c 7.2%?
Is tizanidine (Zanaflex) safe for patients with chronic kidney disease?
In an 80-year-old woman with a gallbladder carcinoma causing a biliary stricture, what are the characteristic imaging appearances and histologic features of the oral cavity, esophagus, stomach, duodenum, ampulla of Vater, and extra-hepatic bile ducts?
What are the components of the cerebral ischemic injury cascade?
What oral morphine dose is equivalent to 4 mg intravenous morphine administered every 4 hours?
Should I get a repeat urine culture and how should persistent urinary urgency/frequency be managed after a recent urinary tract infection?
What cefdinir dose corresponds to 14 mg per kilogram per day?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.